

**SPEAKER AND MODERATOR BIOSKETCHES**  
**WEBINAR 1 - Impact of the Dobbs Decision on Cancer Care:**  
**How Abortion Restrictions Affect Patients and Care Delivery**



**Karen Basen-Engquist, PhD, MPH (Co-Moderator)**  
The University of Texas MD Anderson Cancer Center

Karen Basen-Engquist, PhD, MPH, is the Annie Laurie Howard Research Distinguished Professor in the Department of Behavioral Science and the Director of the Center for Energy Balance in Cancer Prevention and Survivorship at The University of Texas MD Anderson Cancer Center. Dr. Basen-Engquist's research focuses on cancer survivors and high-risk individuals and investigates the role of health behavior interventions in improving physical functioning, optimizing quality of life, and reducing the risk of cancer, cancer recurrence, and other chronic diseases. In addition, she studies intervention methods for behavior change with a focus on distance-based and mHealth interventions and uses innovative real-time methods for assessing symptoms and behavior in cancer patients and survivors. She currently is the co-chair of LIVES, a national trial of a diet and physical activity intervention for ovarian cancer survivors, and has been a multiple PI and a co-investigator on grants to study the use of wearable and home-based sensors in cancer prevention and survivorship research. Her research on the benefits of physical activity for cancer survivors has been translated into a community program to increase physical activity among minority and medically underserved cancer survivors in Houston, Beaumont, Tyler, and El Paso, Texas, funded by the Cancer Prevention and Research Institute of Texas (CPRIT). Dr. Basen-Engquist's research center is working to expand energy balance research at MD Anderson by facilitating collaboration among investigators with interests in basic science, clinical, and population research related to physical activity, nutrition, obesity, and cancer.

Dr. Basen-Engquist is a member of the National Cancer Policy Forum at the National Academy of Medicine and has served as an organizer of NCPF workshops on incorporating physical activity and weight management programs throughout the cancer continuum, patient navigation, and health literacy. She is the past president of the American Society of Preventive Oncology.



**Beth Y. Karlan, MD (Co-Moderator)**

University of California, Los Angeles, Jonsson Comprehensive Cancer Center

Beth Y. Karlan, MD, is Professor and Vice Chair of Women's Health Research in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine, University of California Los Angeles (UCLA). She is also the Director of Cancer Population Genetics at the UCLA-Jonsson Comprehensive Cancer Center. Dr. Karlan's research focuses on ovarian and other women's cancers as well as inherited cancer susceptibility. She has authored over 400 peer-reviewed research publications and for over ten years served as Editor-in-Chief of the scientific journals *Gynecologic Oncology* and *Gynecologic Oncology Reports*. She is an American Cancer Society Clinical Research Professor, has served in many national

leadership roles including president of the Society of Gynecologic Oncology, and has helped train a generation of physicians and scientists. In 2012, Dr. Karlan was appointed by the Obama White House to serve on the National Cancer Advisory Board and in 2015 she was elected to membership in the National Academy of Medicine. Dr. Karlan is a Fellow of the American Society of Clinical Oncology and a member of the National Cancer Policy Forum. Her contributions have been recognized by her peers with multiple awards including a Lifetime Achievement Award from the International Society of Gynecologic Cancer.



**Julie Gralow, MD, FACP, FASCO**

American Society of Clinical Oncology (ASCO)

Dr. Gralow is the Chief Medical Officer and Executive Vice President of ASCO and brings to her role deep expertise in patient care, research, education, and global health.

Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance.

Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the Women's Empowerment Cancer Advocacy Network (WE CAN), she supports patient advocates in low- and middle-resource countries. In addition, she served as an adjunct professor in the University of Washington's Department of Global Health, as a member of the University of Washington's Breast Cancer Equity Initiative, as Medical Director for Women's Cancer-related Population Health at the University of Washington, and as an advisory council member for the Uganda Cancer Institute's adult Hematology/Oncology Fellowship Training Program. Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally.

She is a recognized leader in breast cancer clinical research, and has conducted clinical trials in breast cancer prevention, treatment, and survivorship. Dr. Gralow served in leadership roles for

the SWOG Cancer Research Network funded by the National Cancer Institute (NCI), including as Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.

Before joining ASCO full-time, Dr. Gralow served the Society in a variety of volunteer and leadership roles, including chairing the ASCO Academic Global Oncology Task Force, co-chairing the ASCO Resource Stratified Guideline Advisory Group, and serving on the editorial board of the European Society of Medical Oncology (ESMO)/ASCO Global Curriculum in Medical Oncology.

She also has been involved with numerous other nonprofit organizations, including Team Survivor Northwest, an exercise and fitness program for woman cancer survivors which she co-founded in 1995 and serves as Team Physician; a medical advisory committee member for Cierra Sisters African American Support Group; an advisory board member of Global Focus on Cancer; and a Board member of Peace Island Medical Center, a rural access hospital in Washington State.

Dr. Gralow received her bachelor's degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She trained in internal medicine at Brigham and Women's Hospital at Harvard Medical School and completed a medical oncology fellowship at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.



**Nicole Huberfeld, JD**  
Boston University

Nicole Huberfeld is Edward R. Utley Professor of Health Law at BU School of Public Health (BUSPH) and Professor of Law at BU School of Law, where she is also Co-Director of the BU Program on Reproductive Justice and affiliate faculty with the Center for Antiracism Research and the Medicaid Policy Lab. Her research studies the intersection of health law and constitutional law, examining law as a determinant of health with research on federalism, Medicaid, health reform, and reproductive care. She is the co-author of two leading health law casebooks and many national and international book chapters, law journal articles, peer-reviewed articles, and commentaries. Her

work has been cited in judicial opinions by the U.S. Supreme Court and other federal and state courts. In 2019, Huberfeld won an Excellence in Teaching Award at BUSPH, and she was nominated for teaching awards in 2021 and 2022 at BU Law. Recently, she became Research Director for the Uniform Law Commission's Joint Editorial Board on Health Law. Media quotes include the New York Times, NPR, Washington Post, Bloomberg News, Reuters, Huffington Post, Talking Points Memo, National Law Journal, Congressional Quarterly, Politico, and Univision.



**Reshma Jagsi, MD, DPhil**

Emory University, Winship Cancer Institute

Reshma Jagsi, MD, DPhil, is the Chair of the Department of Radiation Oncology at Emory University. An internationally recognized bioethicist, health services researcher, and clinical trialist who specializes in the care of patients with breast cancer, she is the author of over 400 articles in peer-reviewed journals, including multiple high-impact studies in journals such as the New England Journal of Medicine, the Lancet, and JAMA. Her research has been funded by multiple independent large grants from the National Institutes of Health and philanthropic foundations. Active in organized medicine, she is the current Chair of ASTRO's Ethics Committee and its Committee for Women in Radiation Oncology

and has served on the Board of Directors of ASCO and the Steering Committee of the AAMC's Group on Women in Medicine in Science. She is a member of the National Academies of Science, Engineering, and Medicine's Committee on Women in Science, Engineering, and Medicine. Her contributions have been recognized with her election to the American Society of Clinical Investigation and Association of American Physicians, the Leadership Award of the AAMC's Group on Women in Medicine and Science, LEAD Oncology's Woman of the Year Award, AMWA's Woman in Science Award, and AMSA's Women Leaders Award. She is a fellow of the AAAS, ASCO, ASTRO, AAWR, and the Hastings Center.



**Monica Hagan Vetter, MD**

Baptist Health Medical Group

Dr. Monica Hagan Vetter is a gynecologic oncologist with Baptist Health Medical Group. She did her residency in Obstetrics/Gynecology and her fellowship in Gynecologic Oncology at the Ohio State University. She currently practices in Lexington, Kentucky where she cares for women with gynecologic cancers and precancers.

**PLANNING GROUP BIOSKETCHES**  
**WEBINAR SERIES - Impact of the Dobbs Decision on Cancer Care**



**Karen Basen-Engquist, PhD, MPH (Co-Chair)**

The University of Texas MD Anderson Cancer Center

Karen Basen-Engquist, PhD, MPH, is the Annie Laurie Howard Research Distinguished Professor in the Department of Behavioral Science and the Director of the Center for Energy Balance in Cancer Prevention and Survivorship at The University of Texas MD Anderson Cancer Center. Dr. Basen-Engquist's research focuses on cancer survivors and high-risk individuals and investigates the role of health behavior interventions in improving physical functioning, optimizing quality of life, and reducing the risk of cancer, cancer recurrence, and other chronic diseases. In addition, she studies intervention methods for behavior change with a focus on distance-based and mHealth interventions and uses innovative real-time methods for assessing symptoms and behavior in cancer patients and survivors. She currently is the co-chair of LIVES, a national trial of a diet and physical activity intervention for ovarian cancer survivors, and has been a multiple PI and a co-investigator on grants to study the use of wearable and home-based sensors in cancer prevention and survivorship research. Her research on the benefits of physical activity for cancer survivors has been translated into a community program to increase physical activity among minority and medically underserved cancer survivors in Houston, Beaumont, Tyler, and El Paso, Texas, funded by the Cancer Prevention and Research Institute of Texas (CPRIT). Dr. Basen-Engquist's research center is working to expand energy balance research at MD Anderson by facilitating collaboration among investigators with interests in basic science, clinical, and population research related to physical activity, nutrition, obesity, and cancer.

Dr. Basen-Engquist is a member of the National Cancer Policy Forum at the National Academy of Medicine and has served as an organizer of NCPF workshops on incorporating physical activity and weight management programs throughout the cancer continuum, patient navigation, and health literacy. She is the past president of the American Society of Preventive Oncology.



**Robin Yabroff, PhD, MBA (Co-Chair)**

American Cancer Society

Robin Yabroff, PhD, is an epidemiologist and Scientific Vice President, Health Services Research, at the American Cancer Society. She conducts research on the economic burden of cancer; patterns of cancer care, including high cost prescription drugs; health insurance benefit design; and patient, provider, and health system factors associated with the quality and value of cancer care.

Dr. Yabroff has more than 20 years of health services research experience and currently has adjunct positions within the Department of Medicine, Johns Hopkins University, and the Rollins School of Public Health, Emory University. Prior to joining the American Cancer Society, she held positions within

the Office of Health Policy, Assistant Secretary for Planning and Evaluation (ASPE) in the US Department of Health and Human Services, the Health Services and Economics Branch of the National Cancer Institute, and the faculty of the Lombardi Cancer Center, Georgetown University. She earned her PhD in epidemiology from the Johns Hopkins School of Public Health and received an MBA from the University of Rochester.

Dr. Yabroff has co-authored over 300 peer-reviewed journal articles and invited editorials, commentaries, and book chapters. She is a Deputy Editor for the *Journal of the National Cancer Institute*, a founding member of the editorial board of the *Journal of Cancer Survivorship*, and a member of the editorial board of the *JCO Oncology Practice*. Dr. Yabroff has received multiple National Institutes of Health Merit Awards for her research leadership and mentorship.



**Julie Gralow, MD, FACP, FASCO**  
American Society of Clinical Oncology (ASCO)

Dr. Gralow is the Chief Medical Officer and Executive Vice President of ASCO and brings to her role deep expertise in patient care, research, education, and global health.

Previously, she was the Jill Bennett Endowed Professor of Breast Cancer at the University of Washington School of Medicine, Professor in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, as well as Director of Breast Medical Oncology at the Seattle Cancer Care Alliance.

Dr. Gralow is strongly committed to advancing equity in cancer care. As founder of the Women's Empowerment Cancer Advocacy Network (WE CAN), she supports patient advocates in low- and middle-resource countries. In addition, she served as an adjunct professor in the University of Washington's Department of Global Health, as a member of the University of Washington's Breast Cancer Equity Initiative, as Medical Director for Women's Cancer-related Population Health at the University of Washington, and as an advisory council member for the Uganda Cancer Institute's adult Hematology/Oncology Fellowship Training Program. Dr. Gralow received the ASCO Humanitarian Award in 2018 for her work in empowering women cancer patients and survivors globally.

She is a recognized leader in breast cancer clinical research, and has conducted clinical trials in breast cancer prevention, treatment, and survivorship. Dr. Gralow served in leadership roles for the SWOG Cancer Research Network funded by the National Cancer Institute (NCI), including as Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.

Before joining ASCO full-time, Dr. Gralow served the Society in a variety of volunteer and leadership roles, including chairing the ASCO Academic Global Oncology Task Force, co-chairing the ASCO Resource Stratified Guideline Advisory Group, and serving on the editorial board of the European Society of Medical Oncology (ESMO)/ASCO Global Curriculum in Medical Oncology.

She also has been involved with numerous other nonprofit organizations, including Team Survivor Northwest, an exercise and fitness program for woman cancer survivors which she co-founded in 1995 and serves as Team Physician; a medical advisory committee member for Cierra

Sisters African American Support Group; an advisory board member of Global Focus on Cancer; and a Board member of Peace Island Medical Center, a rural access hospital in Washington State.

Dr. Gralow received her bachelor's degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She trained in internal medicine at Brigham and Women's Hospital at Harvard Medical School and completed a medical oncology fellowship at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle.



**Roy S. Herbst, MD, PhD**

Yale Comprehensive Cancer Center, Yale School of Medicine, and Smilow Cancer Hospital

Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT.

Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His leadership in targeted therapeutics resulted in a 2020 ASCO plenary talk and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the *New England Journal of Medicine*. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. In 2015 and again in 2020, his team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the NCI, which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies.

His work on "umbrella" trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies, such as Lung-MAP. He testified on the subject of modernizing clinical trials during the 21st Century Cures hearing before the US House of Representatives Subcommittee on Health and has served as a prominent figure in the public policy arena, for nine years having served as a member of the National Academy of Medicine's Cancer Policy Forum, for which he organized several meetings focused on policy issues in personalized medicine and tobacco control.

Dr. Herbst is a highly respected clinician- scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has authored or co-authored more than 350 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the *Journal of Clinical Oncology*, *Clinical Cancer Research*, *Lancet*, and the *New England Journal of Medicine*. Work published in *Nature* was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

He is a Fellow of the American Society of Clinical Oncology and a member of the American Association of Cancer Research (AACR), where he serves as an elected member of its board of directors and chairs the Tobacco Task Force. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. In 2019 he was elected to the International Association for the Study of Lung Cancer (IASLC) board of directors. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair of the Southwestern Oncology Group's (SWOG) Lung Committee.

For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th World Conference on Lung Cancer in Vienna, Austria. A team of Yale Cancer Center investigators led by Roy S. Herbst, MD, PhD, was awarded the 2018 Team Science Award from the Association for Clinical and Translational Science (ACTS) for its pioneering work in advancing our understanding of Immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy.



**Nicole Huberfeld, JD**  
Boston University

Nicole Huberfeld is Edward R. Uteley Professor of Health Law at BU School of Public Health (BUSPH) and Professor of Law at BU School of Law, where she is also Co-Director of the BU Program on Reproductive Justice and affiliate faculty with the Center for Antiracism Research and the Medicaid Policy Lab. Her research studies the intersection of health law and constitutional law, examining law as a determinant of health with research on federalism, Medicaid, health reform, and reproductive care. She is the co-author of two leading health law casebooks and many national and international book chapters, law journal articles, peer-reviewed articles, and commentaries. Her

work has been cited in judicial opinions by the U.S. Supreme Court and other federal and state courts. In 2019, Huberfeld won an Excellence in Teaching Award at BUSPH, and she was nominated for teaching awards in 2021 and 2022 at BU Law. Recently, she became Research Director for the Uniform Law Commission's Joint Editorial Board on Health Law. Media quotes include the New York Times, NPR, Washington Post, Bloomberg News, Reuters, Huffington Post, Talking Points Memo, National Law Journal, Congressional Quarterly, Politico, and Univision.



**Beth Y. Karlan, MD**

University of California, Los Angeles, Jonsson Comprehensive Cancer Center

Beth Y. Karlan, MD, is Professor and Vice Chair of Women's Health Research in the Department of Obstetrics and Gynecology at the David Geffen School of Medicine, University of California Los Angeles (UCLA). She is also the Director of Cancer Population Genetics at the UCLA-Jonsson Comprehensive Cancer Center. Dr. Karlan's research focuses on ovarian and other women's cancers as well as inherited cancer susceptibility. She has authored over 400 peer-reviewed research publications and for over ten years served as Editor-in-Chief of the scientific journals *Gynecologic Oncology* and *Gynecologic Oncology Reports*. She is an American Cancer Society Clinical Research Professor, has served in many national

leadership roles including president of the Society of Gynecologic Oncology, and has helped train a generation of physicians and scientists. In 2012, Dr. Karlan was appointed by the Obama White House to serve on the National Cancer Advisory Board and in 2015 she was elected to membership in the National Academy of Medicine. Dr. Karlan is a Fellow of the American Society of Clinical Oncology and a member of the National Cancer Policy Forum. Her contributions have been recognized by her peers with multiple awards including a Lifetime Achievement Award from the International Society of Gynecologic Cancer.



**Alexander Melamed, MD**

Massachusetts General Hospital

Alexander Melamed is an Assistant Professor in the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at New York-Presbyterian/ Columbia University Medical Center. He provides medical and surgical care to women with cancers of the reproductive system including ovarian, uterine, cervical, and vulvar cancer. His research focuses on improving outcomes among people with cancer and promoting the use of robust analytical methods for observational studies in oncology. Dr. Melamed's work has helped to define the role of minimally invasive surgery in gynecologic oncology and identified strategies that reduce unnecessary side effects in the treatment of ovarian cancer, and contributed to a shift in the international standard of care for

the treatment of early-stage cervical cancer. Dr. Melamed is the recipient of career development awards from the National Institute of Health's National Center for Advancing Translational Science, the American Society of Clinical Oncology's Conquer Cancer Foundation, and the Department of Defense's Ovarian Cancer Research Program.



**Kayte Spector-Bagdady, JD, MBioethics**  
University of Michigan

Kayte Spector-Bagdady, JD, MBioethics is an Assistant Professor of Obstetrics and Gynecology and interim Co-Director at the Center for Bioethics and Social Sciences in Medicine and at the University of Michigan Medical School. She is also the Chair of the U-M Research Ethics Committee, the ethicist on the Human Data and Biospecimen Release Committee, and a clinical ethicist. She teaches the Responsible Conduct of Research as well as Research Ethics and the Law and is an Associate Editor of the American Journal of Bioethics.

The overarching goal of Prof. Spector's work is improving the governance of secondary research with health data and specimens to increase the accessibility of data and generalizability of advances across diverse communities.

She is the PI of a National Human Genome Research Institute KO1 studying how and why geneticists select datasets for their research and a National Center for Advancing Translational Sciences RO1 on hospitals sharing patient data with commercial entities. Her recent articles have been published in The New England Journal of Medicine, Science, JAMA, and Nature Medicine, and her research or expertise has appeared in the NY Times, The Washington Post, The Wall Street Journal, TIME, and CNN.

Professor Spector was an Associate Director for President Obama's Presidential Commission for the Study of Bioethical Issues, and is a former Board Member of the American Society for Bioethics & Humanities and practicing FDA law attorney. She graduated from the University of Pennsylvania Law School and School of Medicine after attending Middlebury College.